Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Long-Term Deferred Tax (2022 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $149.7 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 21.38% to $149.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $149.7 million through Dec 2025, down 21.38% year-over-year, with the annual reading at $149.7 million for FY2025, 21.38% down from the prior year.
  • Long-Term Deferred Tax hit $149.7 million in Q4 2025 for Harmony Biosciences Holdings, down from $157.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $201.2 million in Q2 2025 to a low of $81.7 million in Q3 2022.
  • Historically, Long-Term Deferred Tax has averaged $142.9 million across 4 years, with a median of $148.7 million in 2024.
  • Biggest five-year swings in Long-Term Deferred Tax: surged 92.55% in 2024 and later fell 21.38% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $85.9 million in 2022, then skyrocketed by 67.74% to $144.2 million in 2023, then skyrocketed by 32.07% to $190.4 million in 2024, then dropped by 21.38% to $149.7 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for HRMY at $149.7 million in Q4 2025, $157.1 million in Q3 2025, and $201.2 million in Q2 2025.